Pitts Stephanie, Laiho Marikki
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Cancers (Basel). 2022 Nov 24;14(23):5776. doi: 10.3390/cancers14235776.
RNA polymerase I is a highly processive enzyme with fast initiation and elongation rates. The structure of Pol I, with its in-built RNA cleavage ability and incorporation of subunits homologous to transcription factors, enables it to quickly and efficiently synthesize the enormous amount of rRNA required for ribosome biogenesis. Each step of Pol I transcription is carefully controlled. However, cancers have highjacked these control points to switch the enzyme, and its transcription, on permanently. While this provides an exceptional benefit to cancer cells, it also creates a potential cancer therapeutic vulnerability. We review the current research on the regulation of Pol I transcription, and we discuss chemical biology efforts to develop new targeted agents against this process. Lastly, we highlight challenges that have arisen from the introduction of agents with promiscuous mechanisms of action and provide examples of agents with specificity and selectivity against Pol I.
RNA聚合酶I是一种具有高持续性的酶,其起始和延伸速率都很快。聚合酶I的结构,以及其内在的RNA切割能力和与转录因子同源的亚基的整合,使其能够快速有效地合成核糖体生物发生所需的大量rRNA。聚合酶I转录的每一步都受到严格控制。然而,癌症已经劫持了这些控制点,使该酶及其转录永久开启。虽然这给癌细胞带来了极大的好处,但也造成了潜在的癌症治疗弱点。我们综述了目前关于聚合酶I转录调控的研究,并讨论了开发针对这一过程的新型靶向药物的化学生物学研究成果。最后,我们强调了由于引入具有混杂作用机制的药物而出现的挑战,并提供了对聚合酶I具有特异性和选择性的药物实例。